Genmab — April 2018
-
Denmark is on its way. Mono is ok and they have made a draft for 2. line combo. Wil assumably be soc soon. http://www.medicinraadet.dk/media/5467/indstilling-10-behandlingsvejledning-knoglemarvskraeft-myelomatose.pdf
-
Here is the draft protocol page 8 http://www.medicinraadet.dk/media/6275/protokol-10-knoglemarvskraeft.pdf
-
Seems like we are holding in strong hands. But watch, !! - when they release the short positions the bullit is going much stronger and faster than you can buy it for now. - maybe it still falls a bit , But there is no more downside as I see it. Good luck.
-
Ny duobody i klinikken. På side 13 i vedlagte slideshow fra GF anføres JNJ-64407564. Den har ikke tidligere været nævnt! http://files.shareholder.com/downloads/AMDA-KPIBN/138540251x7895654x976323/FA28BE7E-0E02-4A37-8E24-39ACD8F23226/AGM_2018_vfinal_website.pdf
-
-
Den må give en lille milepæl når første patienter doseres
-
hold da op Bulder, dig kan man ikke kører om hjørner med
Men det jeg mente var at den er ny i Gnemabs slideshow. Var f.eks. ikke med i slideshow
efter årsregnskabet! -
Novod: The new DuoBody has the name JNJ-7564 and it started ph I in March 2018. Besides this being a potentially new and interesting myeloma drug over time, we believe it is also positive that JnJ is expanding its Genmab myeloma commitment beyond Darzalex.
-
Takker Bulder

-
og dara?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind